Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-058 in healthy non-elderly and elderly participants
NCT02389881Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-058 in schizophrenia (7 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event at 40 days, Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-Dose at 40 days and 1 more. Started Feb 2015; status: completed.
02
Drugs
TAK-058
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02389881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389881.